Pulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) Study

(NASDAQ:PLSE) HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced the first successful procedures in a multicenter IRB-approved study using Pulse Biosciences’ nsPFA™ Percutaneous Electrode System for the treatment of benign thyroid nodules (BTNs). “Successful procedures for the first enrolled patients in our PRECISE-BTN clinical study for the treatment